Venus Remedies Past Earnings Performance
Past criteria checks 2/6
Venus Remedies has been growing earnings at an average annual rate of 17.2%, while the Pharmaceuticals industry saw earnings growing at 13.7% annually. Revenues have been growing at an average rate of 8.3% per year. Venus Remedies's return on equity is 4.5%, and it has net margins of 3.6%.
Key information
17.2%
Earnings growth rate
16.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 8.3% |
| Return on equity | 4.5% |
| Net Margin | 3.6% |
| Next Earnings Update | 04 Feb 2025 |
Recent past performance updates
Recent updates
Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why
Sep 17
Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%
Jun 14Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt
Jun 13Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%
Mar 14Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)
Oct 31Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly
Jun 03Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)
Jul 15Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
May 31I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease
Mar 30Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge
Feb 24Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?
Feb 01Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching
Nov 16Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?
Mar 11We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt
Jan 14Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 23Is Venus Remedies (NSE:VENUSREM) A Risky Investment?
Sep 22Revenue & Expenses Breakdown
How Venus Remedies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6,146 | 221 | 1,739 | 169 |
| 30 Jun 24 | 6,149 | 285 | 1,734 | 165 |
| 31 Mar 24 | 6,014 | 285 | 1,697 | 158 |
| 31 Dec 23 | 5,619 | 290 | 1,596 | 158 |
| 30 Sep 23 | 5,354 | 255 | 1,527 | 190 |
| 30 Jun 23 | 5,076 | 209 | 1,384 | 203 |
| 31 Mar 23 | 5,555 | 266 | 1,397 | 229 |
| 31 Dec 22 | 5,418 | 157 | 1,353 | 261 |
| 30 Sep 22 | 5,492 | 181 | 1,352 | 249 |
| 30 Jun 22 | 6,119 | 359 | 1,332 | 267 |
| 31 Mar 22 | 6,002 | 407 | 1,281 | 230 |
| 31 Dec 21 | 5,702 | 756 | 1,225 | 193 |
| 30 Sep 21 | 5,684 | 816 | 1,214 | 182 |
| 30 Jun 21 | 5,087 | 715 | 1,243 | 149 |
| 31 Mar 21 | 5,481 | 618 | 1,378 | 158 |
| 31 Dec 20 | 5,320 | 213 | 1,471 | 159 |
| 30 Sep 20 | 4,939 | 87 | 1,431 | 158 |
| 30 Jun 20 | 4,586 | -40 | 1,338 | 144 |
| 31 Mar 20 | 3,407 | -100 | 1,100 | 143 |
| 31 Dec 19 | 3,490 | -161 | 1,026 | 147 |
| 30 Sep 19 | 3,281 | -269 | 995 | 145 |
| 30 Jun 19 | 3,286 | -269 | 960 | 149 |
| 31 Mar 19 | 3,219 | -286 | 928 | 147 |
| 31 Mar 18 | 3,724 | -307 | 972 | 306 |
| 31 Mar 17 | 4,000 | -171 | 409 | 278 |
| 31 Mar 16 | 4,183 | 17 | 437 | 0 |
| 31 Mar 15 | 4,640 | 52 | 496 | 0 |
| 31 Mar 14 | 5,416 | 643 | 775 | 167 |
Quality Earnings: VENUSREM has high quality earnings.
Growing Profit Margin: VENUSREM's current net profit margins (3.6%) are lower than last year (4.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VENUSREM has become profitable over the past 5 years, growing earnings by 17.2% per year.
Accelerating Growth: VENUSREM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VENUSREM had negative earnings growth (-13.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (21.2%).
Return on Equity
High ROE: VENUSREM's Return on Equity (4.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 01:12 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Venus Remedies Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ashish Kushwaha | FirstCall Research |
| Nagaraju Airruva | FirstCall Research |